Corin exploits orthopaedic niche, playing to informed market group
This article was originally published in Clinica
Executive Summary
Orthopaedic implant developer Corin has developed a niche for itself in targeting the young, active population with hip and knee products that are more usually seen as the province of the older patient. And chairman and founder Peter Gibson told Clinica why he does not feel overpowered in the company of the industry's big hitters. Ashley Yeo reports
You may also be interested in...
The Personal Touch: Ortho Implants Challenger Corin Creates Its Own Value Pathway
Mid-size orthopedic implants group Corin is back in the public eye after its recent purchase by a Permira-funded group. Now ready to embark on the next chapter of its development globally, it has a clear growth plan and a firm strategic line on both what it will and will not do as a business.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.